c-Met inhibitor CBT-101

{
  "id": "MLC-T-ONC-012667",
  "term": "c-Met inhibitor CBT-101",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the proto-oncogene hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon administration, CBT-101 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in c-Met-overexpressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/c-met-inhibitor-cbt-101/"
}